Axicabtagene Ciloleucel (Yescarta)

Abstract

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses axicabtagene ciloleucel (Yescarta); cell suspension in patient-specific single-infusion bag, for IV infusion. Indication: For the treatment of adult patients with relapsed or refractory grade 1, 2, or 3a follicular lymphoma (FL) after 2 or more lines of systemic therapy.